Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Baricitinib in Children With Severe Alopecia Areata
jRCT2051220189Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in alopecia areata (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Proportion of participants achieving SALT ≤20 at Week 36. Started May 2023; status: recruiting.
02
Drugs
baricitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on jRCT2051220189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220189.